Speaker illustration

Mr Frederik Ernst Deiman

University Medical Centre Groningen, Groningen (Netherlands (The))

Member of:

Heart Failure Association of the ESC

Frederik Deiman (also known as Frits Deiman) is a cardiovascular researcher focusing on genetic cardiomyopathies and precision medicine. His work integrates disease modeling, patient-derived cardiac tissue, stem cell–based models, and multi-omics approaches, to elucidate disease mechanisms, identify therapeutic targets and evaluate the potential of novel drugs, particularly gene therapy.

Phospholamban cardiomyopathy: from in vitro disease modeling to therapy

Event: HFA Winter Research Meeting 2026

Topic: VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE

Session: Cardiomyopathies

Thumbnail

Phospholamban antisense therapy reduces phospholamban aggregation and enhances calcium and contractile kinetics in human phospholamban cardiomyopathy

Event: Heart Failure 2025

Topic: Gene Therapy, Cell Therapy

Session: Young Investigator Award (YIA) Basic Science

Thumbnail

Phosphoproteomics of phospholamban R14del heart tissue reveals aberrant regulation of calcium handling and contractility

Event: EHRA 2025

Topic: Arrhythmias

Session: Genetics: primary arrhythmia syndromes and sudden cardiac death

Thumbnail

Phosphoproteomics of PLN R14del heart tissue reveals major myocyte degenerate phenotype, and is attenuated by PLN antisense treatment in vitro

Event: ESC Congress 2024

Topic: Cardiomyopathies

Session: Novel mechanisms in arrhythmogenic cardiac diseases

Thumbnail

Phospholamban antisense treatment attenuates hallmarks of disease in PLN R14del human iPSC derived cardiomyocytes

Event: Heart Failure 2023

Topic: Cardiomyopathies

Session: From bedside to bench and back

Thumbnail

ESC 365 is supported by